Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 7Genitourinary 6Head & Neck 3Thoracic 2Sarcoma 2Lymphoid 2Gastrointestinal 2Breast 2Other solid neoplasm 1Other hematologic neoplasm 1CNS 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × bempegaldesleukin × Breast × Clear all
NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03435640 2023-03-08

REVEAL

Nektar Therapeutics

Phase 1/2 Terminated
64 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡